4D Molecular Therapeutics, Inc.
FDMTDrugs in Pipeline
15
Phase 3 Programs
4
Upcoming Catalysts
6
Next Catalyst
Aug 10, 2026
6dMarket Overview
Stock performance and key metrics
6 upcoming, 0 past
FDMT Earnings Report
EPS Est: $-1.04 | FQ end 2026-06
5 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How FDMT's past catalysts played out
11C-choline Injection
Metastatic Prostate Cancer
4D-150 IVT (3E10 vg/eye)
Neovascular Age-Related Macular Degeneration (nAMD)
mycophenolate mofetil
Familial Lipoprotein Lipase Deficiency
EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D-710
Cystic Fibrosis Lung
99mTc-glucarate solution
Acute Coronary Syndrome
AMT-101 (oral)
Ulcerative Colitis
[F 18]HX4
Head and Neck Cancer
[F-18]RGD-K5
Metastatic Breast Cancer
[F-18] FMISO
Head and Neck Cancer
Aflibercept IVT
Neovascular (Wet) Age-Related Macular Degeneration
AMT-101 (oral)-Dose A
Pouchitis
4D-150 IVT
Diabetic Macular Edema
4D-125 IVT Injection
X-Linked Retinitis Pigmentosa
4D-310
Fabry Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
11C-choline Injection | Phase 3 | Metastatic Prostate Cancer | - | - |
4D-150 IVT (3E10 vg/eye) | Phase 3 | Neovascular Age-Related Macular Degeneration (nAMD) | - | - |
mycophenolate mofetil | Phase 3 | Familial Lipoprotein Lipase Deficiency | - | - |
EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Phase 3 | Macular Neovascularization Secondary to Age-Related Macular Degeneration | - | - |
4D-710 | Phase 2 | Cystic Fibrosis Lung | - | - |
99mTc-glucarate solution | Phase 2 | Acute Coronary Syndrome | - | - |
AMT-101 (oral) | Phase 2 | Ulcerative Colitis | - | - |
[F 18]HX4 | Phase 2 | Head and Neck Cancer | - | - |
[F-18]RGD-K5 | Phase 2 | Metastatic Breast Cancer | - | - |
[F-18] FMISO | Phase 2 | Head and Neck Cancer | - | - |
Aflibercept IVT | Phase 2 | Neovascular (Wet) Age-Related Macular Degeneration | - | - |
AMT-101 (oral)-Dose A | Phase 2 | Pouchitis | - | - |
4D-150 IVT | Phase 2 | Diabetic Macular Edema | - | - |
4D-125 IVT Injection | Phase 2 | X-Linked Retinitis Pigmentosa | - | - |
4D-310 | Phase 2 | Fabry Disease | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in 4D Molecular Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 15 drug candidates in 4D Molecular Therapeutics, Inc.'s (FDMT) pipeline across Phase 3, Phase 2. Its lead program is 11C-choline Injection (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is 4D Molecular Therapeutics, Inc.'s next FDA catalyst?→
4D Molecular Therapeutics, Inc.'s (FDMT) next tracked catalyst is a Earnings expected August 10, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track FDMT biotech catalysts?→
Add FDMT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow 4D Molecular Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.